Tanmay S Panchabhai, Shaun F Noronha, Sanish Davis, Vishal M Shinde, Nilima A Kshirsagar, Nithya J Gogtay
{"title":"居住在孟买(Bombay)的古吉拉特邦和马尔瓦迪人CYP2C19活性的评价。","authors":"Tanmay S Panchabhai, Shaun F Noronha, Sanish Davis, Vishal M Shinde, Nilima A Kshirsagar, Nithya J Gogtay","doi":"10.1186/1472-6904-6-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Inherited differences in the metabolism and disposition of drugs, and genetic polymorphisms in the targets of drug therapy (e.g., receptors), can greatly influence efficacy and toxicity of medications. Marked interethnic differences in CYP2C19 (a member of the cytochrome P-450 enzyme superfamily catalyzing phase I drug metabolism) which affects the metabolism of a number of clinically important drugs have been documented. The present study evaluated the activity of CYP2C19 in normal, healthy Gujrati and Marwadi subjects by phenotyping (a western Indian population).</p><p><strong>Methods: </strong>All subjects received 20 mg of omeprazole, which was followed by blood collection at 3 hrs to estimate the metabolic ratio of omeprazole to 5-hydroxyomeprazole. The analysis was done by HPLC.</p><p><strong>Results: </strong>It was seen that 10.36% of this population were poor metabolizers(PM) whereas 89.63% were extensive metabolizers(EM).</p><p><strong>Conclusion: </strong>A genotyping evaluation would better help in identifying population specific genotypes and thus help individualize drug therapy.</p>","PeriodicalId":9196,"journal":{"name":"BMC Clinical Pharmacology","volume":"6 ","pages":"8"},"PeriodicalIF":0.0000,"publicationDate":"2006-10-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/1472-6904-6-8","citationCount":"16","resultStr":"{\"title\":\"Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay).\",\"authors\":\"Tanmay S Panchabhai, Shaun F Noronha, Sanish Davis, Vishal M Shinde, Nilima A Kshirsagar, Nithya J Gogtay\",\"doi\":\"10.1186/1472-6904-6-8\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Inherited differences in the metabolism and disposition of drugs, and genetic polymorphisms in the targets of drug therapy (e.g., receptors), can greatly influence efficacy and toxicity of medications. Marked interethnic differences in CYP2C19 (a member of the cytochrome P-450 enzyme superfamily catalyzing phase I drug metabolism) which affects the metabolism of a number of clinically important drugs have been documented. The present study evaluated the activity of CYP2C19 in normal, healthy Gujrati and Marwadi subjects by phenotyping (a western Indian population).</p><p><strong>Methods: </strong>All subjects received 20 mg of omeprazole, which was followed by blood collection at 3 hrs to estimate the metabolic ratio of omeprazole to 5-hydroxyomeprazole. The analysis was done by HPLC.</p><p><strong>Results: </strong>It was seen that 10.36% of this population were poor metabolizers(PM) whereas 89.63% were extensive metabolizers(EM).</p><p><strong>Conclusion: </strong>A genotyping evaluation would better help in identifying population specific genotypes and thus help individualize drug therapy.</p>\",\"PeriodicalId\":9196,\"journal\":{\"name\":\"BMC Clinical Pharmacology\",\"volume\":\"6 \",\"pages\":\"8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2006-10-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1186/1472-6904-6-8\",\"citationCount\":\"16\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"BMC Clinical Pharmacology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1186/1472-6904-6-8\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"BMC Clinical Pharmacology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1186/1472-6904-6-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Evaluation of the activity of CYP2C19 in Gujrati and Marwadi subjects living in Mumbai (Bombay).
Background: Inherited differences in the metabolism and disposition of drugs, and genetic polymorphisms in the targets of drug therapy (e.g., receptors), can greatly influence efficacy and toxicity of medications. Marked interethnic differences in CYP2C19 (a member of the cytochrome P-450 enzyme superfamily catalyzing phase I drug metabolism) which affects the metabolism of a number of clinically important drugs have been documented. The present study evaluated the activity of CYP2C19 in normal, healthy Gujrati and Marwadi subjects by phenotyping (a western Indian population).
Methods: All subjects received 20 mg of omeprazole, which was followed by blood collection at 3 hrs to estimate the metabolic ratio of omeprazole to 5-hydroxyomeprazole. The analysis was done by HPLC.
Results: It was seen that 10.36% of this population were poor metabolizers(PM) whereas 89.63% were extensive metabolizers(EM).
Conclusion: A genotyping evaluation would better help in identifying population specific genotypes and thus help individualize drug therapy.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
